Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Status:
Completed

Trial end date:
2017-02-28

Target enrollment:

Participant gender:

International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.

Phase 1/Phase 2

Actelion
Idorsia Pharmaceuticals Ltd.